Treating chronic heart failure with reduced ejection fraction (NICE TA773)
1.1 Empagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or
sacubitril valsartan with a beta blocker and, if tolerated, an MRA.
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist